Return to ads
All categories


Posted by
Posting ads for 49 years
Diagnostic test maker Sequenom Inc.

said late Wednesday its first-quarter loss widened on higher expenses due to research and development spending.The company lost $17.5 million, or 29 cents per share, compared with a loss of $8.6 million, or 19 cents per share, during the same period a year prior.

Revenue fell 18 percent to $8.7 million from $10.6 million.Article Controlsemailreprintnewslettercommentssharedel.icio.usDigg It!yahooFacebookrssAnalysts polled by Thomson Reuters expected a loss of 23 cents per share on revenue of $11.2 million.Sequenom ( SQNM - news - people )'s expenses rose 41 percent to $26.5 million, mainly on research and development costs.Meanwhile, consumable revenue remained nearly flat at $4.7 million while system related revenue fell 31 percent to $3.1 million.

Services revenue fell 38 percent to $837.000.The company had been preparing to launch the Down syndrome test SEQureDx in June, but will delay because of employee mishandling of test data and results.Copyright 2009 Associated Press.

All rights reserved.

This material may not be published broadcast, rewritten, or redistributedHow To Maintain FDA StandardsBofA Shareholders VoteGabelli Manager Finds Cheap GrowthStreet Gains On Consumer Spending
Reply to this ad
Recently viewed ads
Saved ads
Please log in to browse your saved adverts or sign up if you don't have an account yet.
Popular Stuff